Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
20.52
-0.84 (-3.93%)
At close: Jan 30, 2026, 4:00 PM EST
20.85
+0.33 (1.61%)
After-hours: Jan 30, 2026, 7:59 PM EST
Monte Rosa Therapeutics Employees
Monte Rosa Therapeutics had 147 employees as of September 30, 2025. The number of employees increased by 14 or 10.53% compared to the same quarter last year.
Employees
147
Change
14
Growth
10.53%
Revenue / Employee
$1,234,952
Profits / Employee
$142,490
Market Cap
1.63B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 147 | 14 | 10.53% |
| Jun 30, 2025 | 142 | 13 | 10.08% |
| Mar 31, 2025 | 142 | 12 | 9.23% |
| Dec 31, 2024 | 134 | 1 | 0.75% |
| Sep 30, 2024 | 133 | 0 | - |
| Jun 30, 2024 | 129 | -4 | -3.01% |
| Mar 31, 2024 | 130 | -3 | -2.26% |
| Dec 31, 2023 | 133 | 10 | 8.13% |
| Sep 30, 2023 | 133 | 15 | 12.71% |
| Jun 30, 2023 | 133 | 29 | 27.88% |
| Mar 31, 2023 | 133 | 38 | 40.00% |
| Dec 31, 2022 | 123 | 30 | 32.26% |
| Sep 30, 2022 | 118 | 24 | 25.53% |
| Jun 30, 2022 | 104 | 21 | 25.30% |
| Mar 31, 2022 | 95 | 35 | 58.33% |
| Dec 31, 2021 | 93 | 33 | 55.00% |
| Sep 30, 2021 | 94 | - | - |
| Jun 30, 2021 | 83 | - | - |
| Mar 31, 2021 | 60 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immunocore Holdings | 493 |
| Agios Pharmaceuticals | 488 |
| Celldex Therapeutics | 186 |
| Precigen | 143 |
| Definium Therapeutics | 74 |
| Tyra Biosciences | 60 |
| RAPT Therapeutics | 60 |
| Oculis Holding AG | 49 |
GLUE News
- 23 days ago - Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewsWire
- 24 days ago - Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation - Seeking Alpha
- 24 days ago - Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 25 days ago - Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects - GlobeNewsWire
- 25 days ago - Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results - GlobeNewsWire
- 6 weeks ago - Why Is Monte Rosa Stock Trading Higher Today? - Benzinga
- 6 weeks ago - Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations - GlobeNewsWire
- 6 weeks ago - Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results - GlobeNewsWire